A definitive or thorough phase 1 QT ECG trial as a requirement for drug safety assessment

https://doi.org/10.1016/j.jelectrocard.2003.11.004Get rights and content

Abstract

Prolongation of the QT interval by noncardiac drugs is the commonest cause of drug delays in development, nonapprovals and withdrawal from after marketing. The new regulatory guidance issued by the FDA-Health Canada ECG Concept document, requires irrespective of pre-clinical cardiac findings a definitive or thorough Phase I trial for all bioactive agents powered to exclude a 5-ms QTc effect (upper confidence interval = 10 ms) since such resolution is usually not possible with the variability inherent in ECG data from the usual trials in the target population. To design a definitive QT trial attention must be given to the sources of QTc duration spontaneous variability. The sources include the proper selection of the sample size, frequency of and method to analyze ECGs, proper correction formula for QT duration, choice of the supratherapeutic dose (required since the trail must be conducted in healthy volunteers rather than the target population) and proper use of a placebo and positive control groups. The positive control group is essential to define the sensitivity of the trial to detect a drug’s effect on cardiac repolarization. An approach to interpretation of the resulting ECG data from the trial is provided.

References (13)

There are more references available in the full text version of this article.

Cited by (47)

  • Review of T-wave morphology-based biomarkers of ventricular repolarisation using the surface electrocardiogram

    2012, Biomedical Signal Processing and Control
    Citation Excerpt :

    Pharmaceutical companies are justifiably concerned about drug-induced QT prolongation because every drug associated with ventricular arrhythmia has been shown to prolong the QT interval [5]. Furthermore, QT prolongation is now the primary cause of delays in drug development, the non-approval of candidate drugs and the withdrawal of approved drugs from the market [6,7]. Despite QT interval prolongation being the standard indicator (or biomarker) of cardiac safety in clinical trials, there are several limitations associated with the QT interval.

  • Increased survival with enzalutamide in prostate cancer after chemotherapy

    2012, New England Journal of Medicine
    Citation Excerpt :

    Liver-function abnormalities were reported as adverse events in 1% of patients receiving enzalutamide and in 2% of those receiving placebo. A comprehensive evaluation of electrocardiographic data, including the QT interval and the QT interval corrected for heart rate (QTc), revealed no clinically relevant changes in heart rate, atrioventricular conduction, cardiac depolarization, or effect on cardiac repolarization as determined by means of the QTc according to Fridericia's formula.21 Five of the 800 patients in the enzalutamide group (0.6%) were reported by the investigators to have had a seizure; no seizures were reported in the placebo group.

View all citing articles on Scopus
View full text